Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 in Advanced Cutaneous Squamous Cell Carcinoma
NCT05888844Phase 2Terminated
- Sponsor
- Incyte
- Start
- Oct 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of incb099280 in cutaneous squamous cell carcinoma (cSCC) (4 arms), sponsored by Incyte. Primary endpoints: Objective Response Rate up to 2 years, Treatment-emergent Adverse Events and 1 more. Started Oct 2023; status: terminated.
02
Drugs
incb099280
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT05888844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05888844.